RBC Capital: European Medtech Firms Show Minimal Middle East and Energy Risk Exposure 
Eli Lilly and Insilico Medicine Forge $2.75 Billion AI-Driven Drug Discovery Deal 
China's Services Sector Maintains Growth Streak Despite March Slowdown 
Gold Prices Slip in Asia as Iran Strait Deadline Looms 
Oil Prices Surge as U.S.-Iran Conflict Threatens Global Supply 
Morgan Stanley: Fed Rate Cuts Still on Track Despite Oil-Driven Inflation 
Ukrainian Drones and the #MadeByHousewives Movement: Kyiv Fires Back at Rheinmetall CEO 
U.S. Dollar Climbs as Trump Escalates Rhetoric Against Iran 
China's Energy Resilience Shields Economy From Global Oil Shock, Goldman Sachs Says 
MATCH Act Targets ASML and Chinese Chipmakers in New U.S. Export Crackdown 
U.S. Warplane Shot Down by Iran Amid Escalating Middle East Conflict 
Japan Signals Readiness to Intervene as Yen Weakens Toward 160 Per Dollar 
Vietnam GDP Growth Slows in Q1 2026 Amid Middle East Oil Crisis 
Europe's Aviation Sector on Track to Meet 2025 Green Fuel Mandate 
Cathay Pacific Holds Firm on Flight Capacity Amid Middle East Conflict and Rising Fuel Costs 
Nike Beats Q3 Estimates but China Weakness and Margin Pressure Weigh on Outlook 
Gold Prices Drop as Trump Escalates Iran Threats, Oil Surges 
Korea Ginseng Corporation inaugurated its research and development (R&D) center in California. The leading South Korean ginseng producer said on Wednesday, March 15, that it has set up a facility in the United States to expand its presence in the American market while also boosting its sales overseas.
Korea Ginseng Corp. is the maker of the no. 1 ginseng brand in the world known as CheongKwanJang. The opening of its R&D center in the U.S. is a major step toward increasing its market share in the region. Moreover, the center was built so the company can continue developing Korean ginseng into a product that will suit the preference of Americans.
As per The Korea Herald, the ginseng products manufacturer said that with its new R&D center, it would conduct research to find ways of enhancing and broadening the use of its flagship red ginseng products currently being sold in the U.S.
The company especially wants to bolster its products' capability of improving customers' immunity and memory and reducing fatigue. Aside from product development, the center will also serve as a hub that will manage the manufacturing process and quality control of the health products that will be made there.
Korea Ginseng Corp. mentioned its R&D in California will further function as an office for its business ventures in neighboring foreign markets, including Central and South America. The facility will collect data about health drinks and food markets so the company can improve its products based on the information.
"Our US R&D Center will contribute to the construction of local production infrastructure while strengthening the development of customized ginseng products for local consumers," KGC's chief executive officer, Heo Chul Ho, said during the R&D center's inauguration. "The U.S. R&D center will contribute to building infrastructure for a localized manufacturing line as well as strengthening development for localized products."
In a separate press release, the CEO of KGC US, Heung Sil Lee, further said, "This will be a momentous year for our global business. As we meet the unique needs of our U.S. customers by actively developing products specifically tailored to their lifestyles."
